About a month ago, a trial jury awarded Johnson & Johnson (J&J) its first win out of four different Talcum Power trials in St. Louis, MO. The outcome of the other three trials resulted in verdicts in favor of the plaintiffs, with juries ordering the company to pay nearly $200 million in reparations for their actions. J&J was found to be guilty of failing to warn its consumers of the potential health risks associated with talcum powder. The next trial for Talcum Power will begin on April 10, 2017.
The plaintiff in April’s trial is Lois Slemp, who was diagnosed with Stage 3 ovarian cancer, combined with a recurrence and metastasis to her liver. Similar to the other four plaintiffs in the trials, Slemp believes she developed ovarian cancer after multiple years of the use of J&J’s talcum powder products, which was designed for genital powdering.
The chemotherapy that Slemp has had to endure as a result of her illness has weakened the lining of the her heart so drastically, that she suffered a heart attack this past December. Due to the heart attack, she then became incapable of undergoing surgery for a resection of the liver metastasis. Because of her inability to have the surgery, she has since been forced to submit to additional chemotherapy, thus risking another heart attack.
Although Slemp’s trial was originally supposed to take place at a later time, her attorneys filed a motion this past December to have her case advanced to trial sooner, due to her declining health. Although the court initially denied the motion, since the selection of plaintiffs typically alternates between parties, the court has since decided to grant the motion to speed up the trial date, to make ensure that she gets her voice heard during her day in court.